Daniel Quirk

1.6k total citations
23 papers, 854 citations indexed

About

Daniel Quirk is a scholar working on Oncology, Epidemiology and Genetics. According to data from OpenAlex, Daniel Quirk has authored 23 papers receiving a total of 854 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Epidemiology and 8 papers in Genetics. Recurrent topics in Daniel Quirk's work include Inflammatory Bowel Disease (8 papers), Microscopic Colitis (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Daniel Quirk is often cited by papers focused on Inflammatory Bowel Disease (8 papers), Microscopic Colitis (6 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Daniel Quirk collaborates with scholars based in United States, Italy and Canada. Daniel Quirk's co-authors include Paul Akerman, David A. Iannitti, Chinyu Su, Nervin Lawendy, Howard Safran, Bruce E. Sands, Cynthia Schaeffer, K. Peter Etzkorn, David Bernstein and Douglas K. Rex and has published in prestigious journals such as Gastroenterology, International Journal of Radiation Oncology*Biology*Physics and The American Journal of Gastroenterology.

In The Last Decade

Daniel Quirk

23 papers receiving 830 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Quirk United States 11 360 265 198 179 170 23 854
Alessandro Ribechini Italy 15 375 1.0× 231 0.9× 67 0.3× 118 0.7× 111 0.7× 38 1.1k
David Simansky Israel 19 258 0.7× 412 1.6× 32 0.2× 39 0.2× 130 0.8× 43 1.1k
A Bertrand France 7 648 1.8× 214 0.8× 82 0.4× 18 0.1× 70 0.4× 8 965
Joung‐Ho Han South Korea 21 434 1.2× 706 2.7× 31 0.2× 35 0.2× 147 0.9× 122 1.3k
Kyung Young Chung South Korea 19 337 0.9× 400 1.5× 32 0.2× 22 0.1× 153 0.9× 53 1.2k
James M. McLoughlin United States 16 287 0.8× 290 1.1× 31 0.2× 12 0.1× 104 0.6× 41 705
Stefanie Ziegler Italy 12 128 0.4× 153 0.6× 46 0.2× 15 0.1× 41 0.2× 17 599
Kyoji Hirai Japan 15 142 0.4× 290 1.1× 20 0.1× 36 0.2× 35 0.2× 59 841
P J George United Kingdom 17 439 1.2× 238 0.9× 106 0.5× 105 0.6× 50 0.3× 41 1.1k
Andrea O. Tal Germany 12 429 1.2× 273 1.0× 10 0.1× 26 0.1× 58 0.3× 24 979

Countries citing papers authored by Daniel Quirk

Since Specialization
Citations

This map shows the geographic impact of Daniel Quirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Quirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Quirk more than expected).

Fields of papers citing papers by Daniel Quirk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Quirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Quirk. The network helps show where Daniel Quirk may publish in the future.

Co-authorship network of co-authors of Daniel Quirk

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Quirk. A scholar is included among the top collaborators of Daniel Quirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Quirk. Daniel Quirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Long, Millie D., Russell D. Cohen, Timothy W. Smith, et al.. (2021). Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis. Digestive Diseases. 40(5). 553–564. 8 indexed citations
2.
Long, Millie D., Timothy W. Smith, Marco DiBonaventura, et al.. (2019). Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States. Inflammatory Bowel Diseases. 26(6). 941–948. 9 indexed citations
3.
Regueiro, Miguel, Jami Kinnucan, Ryan C. Ungaro, et al.. (2019). 798 Predictors of Delayed Response to Tofacitinib: Results of the OCTAVE Open Study for Delayed Responders. The American Journal of Gastroenterology. 114(1). S462–S462. 1 indexed citations
4.
Sands, Bruce E., Pam R. Taub, Alessandro Armuzzi, et al.. (2019). Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 18(1). 123–132.e3. 80 indexed citations
5.
Hanauer, Stephen B., David T. Rubin, Paolo Gionchetti, et al.. (2019). 836 Tofacitinib Efficacy in Patients With Moderate to Severe Ulcerative Colitis: Subgroup Analyses of OCTAVE Induction 1 & 2 and OCTAVE Sustain by 5-Aminosalicylates Use. The American Journal of Gastroenterology. 114(1). S483–S484. 2 indexed citations
6.
Rubin, David T., Marla Dubinsky, Milan Lukáš, et al.. (2019). Tu1729 – Long-Term Efficacy of Tofacitinib in Patients Who Received Extended Induction Therapy: Results of the Octave Open Study for Tofacitinib Delayed Responders. Gastroenterology. 156(6). S–1102. 1 indexed citations
7.
Rex, Douglas K., Raj Bhandari, Taddese Desta, et al.. (2018). A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointestinal Endoscopy. 88(3). 427–437.e6. 196 indexed citations
8.
Smith, Timothy W., et al.. (2018). Dose Escalation and Treatment Patterns of Advanced Therapies Used to Treat Ulcerative Colitis: A Retrospective Database Analysis in the United States. The American Journal of Gastroenterology. 113(Supplement). S353–S353. 3 indexed citations
9.
Chalikonda, Divya, et al.. (2018). Mo1163 - Gastrointestinal Bleeding in Patients on Novel Oral Anticoagulants Compared to Warfarin: Localization and Prevention. Gastroenterology. 154(6). S–693. 1 indexed citations
10.
Rubin, David T., Satoshi Motoya, Stefan Schreiber, et al.. (2018). Tofacitinib 15 Milligrams Twice Daily for Patients With Moderate to Severe Ulcerative Colitis: Results From 8-Week Induction Studies OCTAVE Induction 1 & 2. The American Journal of Gastroenterology. 113(Supplement). S403–S403. 2 indexed citations
11.
Feagan, Brian G., Marla Dubinsky, Milan Lukáš, et al.. (2018). Sa1742 - Efficacy and Safety of an Additional 8 Weeks of Tofacitinib Induction Therapy: Results of the Octave Open Study for Tofacitinib 8-Week Induction Non-Responders. Gastroenterology. 154(6). S–377. 6 indexed citations
12.
Tofani, Christina, et al.. (2016). Rectal Blue Nevus: Distinguishing Features of a Rare Entity. ACG Case Reports Journal. 3(1). e168–e168. 2 indexed citations
13.
Findlay, Victoria J., Cindy Wang, Lourdes M. Nogueira, et al.. (2014). SNAI2 Modulates Colorectal Cancer 5-Fluorouracil Sensitivity through miR145 Repression. Molecular Cancer Therapeutics. 13(11). 2713–2726. 53 indexed citations
14.
Walter, James, Apurva Patel, Rebecca Matro, et al.. (2013). The Impact of Diet Liberalization on Bowel Preparation for Colonoscopy. The American Journal of Gastroenterology. 108. S162–S162. 7 indexed citations
15.
Jackson, Whitney E., Vaibhav Mehendiratta, Juan Palazzo, et al.. (2013). Boerhaave's syndrome as an initial presentation of eosinophilic esophagitis: a case series.. PubMed. 26(2). 166–169. 12 indexed citations
16.
Safran, Howard, David A. Iannitti, Daniel Quirk, et al.. (2002). Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase i trial. International Journal of Radiation Oncology*Biology*Physics. 54(1). 137–141. 50 indexed citations
17.
Safran, Howard, Todd T. Moore, David A. Iannitti, et al.. (2001). Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics. 49(5). 1275–1279. 54 indexed citations
18.
Safran, Howard, Margaret M. Steinhoff, Shamlal Mangray, et al.. (2001). Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. 24(5). 496–499. 134 indexed citations
19.
Petris, Giovanni De, et al.. (1999). Lymphoepithelioma-like carcinoma of the colon in a patient with hereditary nonpolyposis colorectal cancer.. Archives of Pathology & Laboratory Medicine. 123(8). 720–4. 40 indexed citations
20.
Quirk, Daniel, David W. Rattner, Carlos Fernández-del Castillo, Andrew L. Warshaw, & William R. Brugge. (1997). The use of endoscopic ultrasonography to reduce the cost of treating ampullary tumors. Gastrointestinal Endoscopy. 46(4). 334–337. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Ribechini Breakdown of academic impact, for papers by David Simansky Breakdown of academic impact, for papers by A Bertrand Breakdown of academic impact, for papers by Joung‐Ho Han Breakdown of academic impact, for papers by Kyung Young Chung Breakdown of academic impact, for papers by James M. McLoughlin Breakdown of academic impact, for papers by Stefanie Ziegler Breakdown of academic impact, for papers by Kyoji Hirai Breakdown of academic impact, for papers by P J George Breakdown of academic impact, for papers by Andrea O. Tal
Rankless by CCL
2026